GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.
Recognizing the challenges of increasing imaging volume and workforce attrition in radiology, GE HealthCare has launched MyBreastAI Suite with the goal of facilitating improved breast cancer detection on mammography exams while streamlining radiology workflows with artificial intelligence (AI) tools.
MyBreastAI Suite, an all-in-one AI platform geared to detection and assessment of breast cancer, features three AI applications developed by iCAD: ProFound AI for DBT (digital breast tomosynthesis), SecondLook for 2D Mammography, and PowerLook Density Assessment.
Studies have shown an 8 percent increase in sensitivity, a 6.9 percent increase in specificity and a 52 percent decrease of reading time with ProFoundAI for DBT, according to GE HealthCare. After radiologists have reviewed images from GE HealthCare’s full-field digital mammography (FFDM) devices, the company said they can utilize the SecondLook for 2D Mammography application to check for regions of interest they may have missed.
GE HealthCare also noted that the AI-powered mammogram analysis of PowerLook Density Assessment facilitates standardized reporting and risk stratification with breast density evaluation.
“Through this new all-in-one AI platform designed to offer radiologists enhanced clinical decision support and streamlined workflows, clinicians will be able to deliver more timely, accurate and personalized breast care in their practices today,” said Mario Lois, the general manager of AI for Women’s Health at GE HealthCare. “We know that early detection is key and AI solutions show great promise in advancing breast cancer screening and transforming workflow for radiologists.”
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
